Introduction:
Bristol Myers Squibb invests US$400 million to expand its campus in Dublin, Ireland, by incorporating a new sterile drug product facility.
Features:
The investment aims to expand manufacturing and laboratory capacity in Cruiserath, with a focus on supporting the manufacturing of bulk drug substance (SDP). This expansion will involve the integration of new technologies and capabilities into the existing operations.
The campus will incorporate advanced technologies and capabilities to further support the manufacturing of SDP. By colocating drug substance and drug product manufacturing alongside existing global testing capabilities, this strategic move enhances agility in the global supply chain, benefiting patients worldwide.
The expansion is expected to generate approximately 350 new roles in Ireland. These positions will contribute to workforce, with the total number of direct employees at the Cruiserath campus projected to exceed 1,000.
In efforts to strengthen the commercial and pipeline portfolio across multiple therapeutic domains including oncology, immunology, and haematology, an additional 350 roles are anticipated to be created in Ireland as part of this investment.
Construction is set to commence in March 2024, following planning approval, with completion expected in 2026.
Specifications:
Name Bristol Myers Squibb
Type Expansion
Budget US$400 million
Year 2026
